SWITCHING OUT OF CLASS OR TO ANOTHER ANTI-TNF AGENT IS THE BEST STRATEGY FOR CLINICAL EFFICACY AND TREATMENT PERSISTENCE IN IBD PATIENTS WITH ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF

被引：0
|
作者：
Anjie, Suzanne I.
Hanzel, Jurij
Gecse, Krisztina B.
D'Haens, Geert
Brandse, Johannan F.
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1774
引用
收藏
页码：S1120 / S1121
页数：2
相关论文
共 50 条
  • [41] Anti-TNF agent drug survival in patients with IBD: real-world comparisons of individual anti-TNF agents based on the Swedish National Quality Registry for IBD (SWIBREG)
    Visuri, I.
    Eriksson, C.
    Mardberg, E.
    Grip, O.
    Gustavsson, A.
    Hjortswang, H.
    Karling, P.
    Montgomery, S.
    Myrelid, P.
    Olen, O.
    Ludvigsson, J. F.
    Halfvarson, J.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S443 - S444
  • [42] IBD Antibodies to anti-TNF therapy-consequences for IBD management
    van Deen, Welmoed K.
    Hommes, Daniel W.
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2013, 10 (08) : 446 - 448
  • [43] Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug
    Hyrich, K. L.
    Lunt, M.
    Dixon, W. G.
    Watson, K. D.
    Symmons, D. P. M.
    RHEUMATOLOGY, 2008, 47 (07) : 1000 - 1005
  • [44] Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis
    Johnston, Stephen S.
    Turpcu, Adam
    Shi, Nianwen
    Fowler, Robert
    Chu, Bong-Chul
    Alexander, Kimberly
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2013, 43 (01) : 39 - 47
  • [45] Does Development of Adverse Events With the First Anti-TNF Agent Increase the Risk of Developing Adverse Events With Other Anti-TNF Agent in Patients With IBD?
    Blonski, Wojciech
    Osterman, Mark T.
    Mac Dennott, Richard P.
    Sonu, Irene
    Brensinger, Colleen M.
    Lin, Ming V.
    Lichtenstein, Gary
    GASTROENTEROLOGY, 2010, 138 (05) : S695 - S695
  • [46] Letter: immunogenicity of anti-TNF in elderly IBD patients
    Paul, Stephane
    Roblin, Xavier
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (03) : 336 - 336
  • [47] PPIs and anti-TNF in patients with IBD: a forbidden combination?
    Wellens, Judith
    Sabino, Joao
    Vermeire, Severine
    GUT, 2021, 70 (12) : 2397 - +
  • [48] Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
    Gisbert, Javier P.
    Chaparro, Maria
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (22)
  • [49] The Immunogenicity to the First Anti-TNF Therapy Determines the Outcome of Switching to a Second Anti-TNF in Spondyloarthritis Patients.
    Plasencia, Chamaida
    Pascual-Salcedo, Dora
    Garcia-Carazo, Sara
    Bonilla, Gema
    Lojo, Leticia
    Nuno, Laura
    Villalba, Alejandro
    Peiteado, Diana
    Castillo-Gallego, Concepcion, Jr.
    Arribas, Florencia
    Nagore, Daniel
    Martin-Mola, E.
    Balsa, Alejandro
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S238 - S238
  • [50] Utility of Measuring Serum Concentrations of Anti-TNF Agents and Anti-Drug Antibodies in Inflammatory Bowel Disease
    Guerra, Ivan
    Chaparro, Maria
    Bermejo, Fernando
    Gisbert, Javier P.
    CURRENT DRUG METABOLISM, 2011, 12 (06) : 594 - 598
12345